Emerging treatment options for extraintestinal manifestations in IBD. Issue 4 (26th August 2020)

• Record Type: Journal Article
• Authors: Greuter, Thomas; Rieder, Florian; Kucharzik, Torsten; Peyrin-Biroulet, Laurent; Schoepfer, Alain M; Rubin, David T; Vavricka, Stephan R
• Is Part Of: Gut. Volume 70:Issue 4(2021)
• Page Start: 796
• Page End: 802
• Publication Date: 2020-08-26
• Subjects: arthritis -- IBD clinical -- TNF; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2020-322129
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Extraintestinal manifestations (EIMs) are frequently observed in IBDs and contribute considerably to morbidity and mortality. They have long been considered a difficult to treat entity due to limited therapy options, but the increasing use of anti-tumour necrosis factors has dramatically changed the therapeutic approach to EIM in recent years. Newly emerging therapies such as JAK inhibitors and anti-interleukin 12/23 will further shape the available armamentarium. Clinicians dealing with EIMs in everyday IBD practice may be puzzled by the numerous available biological agents and small molecules, their efficacy for EIMs and their potential off-label indications. Current guidelines on EIMs in IBD do not include treatment algorithms to help practitioners in the treatment decision-making process. Herein, we summarise knowledge on emerging biological treatment options and small molecules for EIMs, highlight current research gaps, provide therapeutic algorithms for EIM management and shed light on future strategies in the context of IBD-related EIMs.